784 related articles for article (PubMed ID: 8522171)
1. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
Bckström M; Holmgren J; Schödel F; Lebens M
Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
[TBL] [Abstract][Full Text] [Related]
2. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit.
Bäckström M; Lebens M; Schödel F; Holmgren J
Gene; 1994 Nov; 149(2):211-7. PubMed ID: 7525413
[TBL] [Abstract][Full Text] [Related]
3. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
4. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
Schödel F; Moriarty AM; Peterson DL; Zheng JA; Hughes JL; Will H; Leturcq DJ; McGee JS; Milich DR
J Virol; 1992 Jan; 66(1):106-14. PubMed ID: 1370083
[TBL] [Abstract][Full Text] [Related]
5. Gene fusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusion protein.
Shi CH; Cao C; Xhig JS; Li J; Ma QJ
Vaccine; 1995 Jul; 13(10):933-7. PubMed ID: 7483767
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of ganglioside GM(1)-binding ability, pentamer formation, and epitopes of cholera toxin B (CTB) subunits and CTB/heat-labile enterotoxin B subunit chimeras.
Jobling MG; Holmes RK
Infect Immun; 2002 Mar; 70(3):1260-71. PubMed ID: 11854209
[TBL] [Abstract][Full Text] [Related]
7. Significance of Enterotoxigenic Escherichia coli (ETEC) Heat-Labile Toxin (LT) Enzymatic Subunit Epitopes in LT Enterotoxicity and Immunogenicity.
Huang J; Duan Q; Zhang W
Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29802193
[TBL] [Abstract][Full Text] [Related]
8. Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination.
Sanchez J; Johansson S; Löwenadler B; Svennerholm AM; Holmgren J
Res Microbiol; 1990; 141(7-8):971-9. PubMed ID: 2101488
[TBL] [Abstract][Full Text] [Related]
9. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1.
Aguilar A; Carrazana Y; Duarte CA
Biomol Eng; 2001 Oct; 18(3):117-24. PubMed ID: 11566603
[TBL] [Abstract][Full Text] [Related]
10. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.
Lian T; Bui T; Ho RJ
Vaccine; 1999 Nov; 18(7-8):604-11. PubMed ID: 10547418
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of viral B-cell epitopes inserted into two surface loops of the Escherichia coli K12 LamB protein and expressed in an attenuated aroA strain of Salmonella typhimurium.
Wang J; Michel V; Leclerc C; Hofnung M; Charbit A
Vaccine; 1999 Jan; 17(1):1-12. PubMed ID: 10078601
[TBL] [Abstract][Full Text] [Related]
12. Expression of heterologous peptides at two permissive sites of the MalE protein: antigenicity and immunogenicity of foreign B-cell and T-cell epitopes.
Martineau P; Guillet JG; Leclerc C; Hofnung M
Gene; 1992 Apr; 113(1):35-46. PubMed ID: 1373395
[TBL] [Abstract][Full Text] [Related]
13. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
14. Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit.
González RA; Sánchez J; Holmgren J; López S; Arias CF
Gene; 1993 Nov; 133(2):227-32. PubMed ID: 7693553
[TBL] [Abstract][Full Text] [Related]
15. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.
von Brunn A; Brand M; Reichhuber C; Morys-Wortmann C; Deinhardt F; Schödel F
Vaccine; 1993; 11(8):817-24. PubMed ID: 7689283
[TBL] [Abstract][Full Text] [Related]
16. Creating hybrid proteins by insertion of exogenous peptides into permissive sites of a class A beta-lactamase.
Ruth N; Quinting B; Mainil J; Hallet B; Frère JM; Huygen K; Galleni M
FEBS J; 2008 Oct; 275(20):5150-60. PubMed ID: 18793326
[TBL] [Abstract][Full Text] [Related]
17. Immunoactive chimeric ST-LT enterotoxins of Escherichia coli generated by in vitro gene fusion.
Sanchez J; Uhlin BE; Grundström T; Holmgren J; Hirst TR
FEBS Lett; 1986 Nov; 208(2):194-8. PubMed ID: 2430831
[TBL] [Abstract][Full Text] [Related]
18. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
19. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
[TBL] [Abstract][Full Text] [Related]
20. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
